- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06335173
초기 알츠하이머병 참가자를 대상으로 ACU193 정맥 주사의 유효성 및 안전성을 평가하기 위한 연구(ALTITUDE-AD) (ALTITUDE-AD)
초기 알츠하이머병에서 ACU193 정맥 주사의 효능과 안전성을 평가하기 위한 2/3상 이중 맹검, 무작위, 위약 대조 적응 설계 시험
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일
- Charité - Universitaetsmedizin Berlin
-
Cologne, 독일
- University Hospital of Cologne
-
Mannheim, 독일
- Zentralinstitut für seelische Gesundheit
-
Munich, 독일
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
-
-
California
-
Carlsbad, California, 미국, 92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton, California, 미국, 92835
- Neurology Center of North Orange County
-
Irvine, California, 미국, 92614
- Irvine Medical Research
-
Long Beach, California, 미국, 90804
- Healthy Brain Research
-
Santa Ana, California, 미국, 92705
- Syrentis Clinical Research
-
Sherman Oaks, California, 미국, 91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk, Connecticut, 미국, 06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis, Florida, 미국, 33462
- JEM Research Institute
-
Bradenton, Florida, 미국, 34205
- Bradenton Research Center
-
Coral Gables, Florida, 미국, 33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach, Florida, 미국, 33445
- Brain Matters Research
-
Homestead, Florida, 미국, 33032
- Coral Clinical Research
-
Lady Lake, Florida, 미국, 32159
- K2 Medical Research - Villages
-
Miami, Florida, 미국, 33126
- Finlay Medical Research
-
Naples, Florida, 미국, 34105-8522
- Aqualane Clinical Research
-
Ocala, Florida, 미국, 34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange, Florida, 미국, 32127
- Progressive Medical Research
-
Stuart, Florida, 미국, 34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa, Florida, 미국, 33607
- K2 Medical Research - Tampa
-
The Villages, Florida, 미국, 32162
- Charter Research - Lady Lake
-
Wellington, Florida, 미국, 33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park, Florida, 미국, 32789
- Conquest Research
-
Winter Park, Florida, 미국, 32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus, Georgia, 미국, 31909
- Columbus Memory Center
-
Decatur, Georgia, 미국, 30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook, Illinois, 미국, 60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton, Massachusetts, 미국, 02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg, Mississippi, 미국, 39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth, New Hampshire, 미국, 03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield, New Jersey, 미국, 07081
- The Cognitive and Research Center of New Jersey
-
Toms River, New Jersey, 미국, 08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, 미국, 12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews, North Carolina, 미국, 28105
- AMC Research
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Summit Research Network
-
-
Pennsylvania
-
Abington, Pennsylvania, 미국, 19001
- Abington Neurological Associates
-
Norristown, Pennsylvania, 미국, 19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, 미국, 02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova, Tennessee, 미국, 38018
- Neurology Clinic. P.C
-
Knoxville, Tennessee, 미국, 37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin, Texas, 미국, 78757
- Senior Adult Specialty Research
-
Beaumont, Texas, 미국, 77702
- Gadolin Research, LLC
-
Dallas, Texas, 미국, 75231
- Kerwin Medical Center
-
-
-
-
-
Barcelona, 스페인
- Fundacio ACE
-
Donostia / San Sebastian, 스페인
- Policlínica Gipuzkoa
-
Getxo, 스페인
- Cae Oroitu
-
Madrid, 스페인
- Hospital Ruber
-
Seville, 스페인
- Hospital Victoria Eugenia
-
Valencia, 스페인
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès, Barcelona, 스페인
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva, Zaragoza, 스페인
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
-
Bristol, 영국
- Re:Cognition Health - Bristol
-
-
Greater London
-
London, Greater London, 영국
- Re:Cognition Health - London
-
London, Greater London, 영국
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester, Hampshire, 영국
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell, Lanarkshire, 영국
- Neuroclin Glasgow
-
-
Lancashire
-
Preston, Lancashire, 영국
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford, Surrey, 영국
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield, Yorkshire, 영국
- Panthera Biopartners - Sheffield
-
-
-
-
British Columbia
-
Kelowna, British Columbia, 캐나다
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa, Ontario, 캐나다
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto, Ontario, 캐나다
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park, Quebec, 캐나다
- MoCA Research and Innovations
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
실험적: DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
위약 비교기: DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
실험적: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
기간: Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
치료 관련 부작용(TEAE)이 발생한 참가자 수
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
심각한 부작용(SAE) 및 특별 관심 부작용(AESI)이 발생한 참가자 수
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
TEAE로 인해 중단 또는 탈퇴한 참가자 수
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
항마약항체(ADA) 및 중화항체를 보유한 참가자 수
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
자기공명영상(MRI)으로 측정한 부종/삼출을 동반한 아밀로이드 관련 영상 이상(ARIA-E) 및 출혈/헤모시데린 침착을 동반한 ARIA(ARIA-H)가 있는 참가자 수
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
참가자 하위 집합에서 ACU193의 CSF 농도
기간: 76주차까지
|
76주차까지
|
|
|
센틸로이드의 양전자 방출 단층촬영(PET)으로 측정한 아밀로이드 플라크 로드 또는 침착의 기준선 변화
기간: 76주차까지의 기준선
|
76주차까지의 기준선
|
|
|
전체 뇌 부피, 심실 부피 및 선택된 관심 영역의 부피에 대한 vMRI(체적 자기 공명 영상)의 기준선 변화
기간: 76주차까지의 기준선
|
76주차까지의 기준선
|
|
|
아밀로이드, 타우 및 기타 신경퇴행성 바이오마커의 CSF 농도 기준선 대비 변화
기간: 76주차까지의 기준선
|
76주차까지의 기준선
|
|
|
참가자 하위 집합에서 아밀로이드, 타우 및 기타 신경퇴행성 바이오마커의 CSF 농도 기준선 대비 변화
기간: 76주차까지의 기준선
|
76주차까지의 기준선
|
|
|
아밀로이드, 타우 및 기타 신경변성 바이오마커의 혈액 농도 기준선 대비 변화
기간: 76주차까지의 기준선
|
76주차까지의 기준선
|
|
|
IADRS로 측정한 시간 절약 분석을 사용하여 평가한 위약과 비교한 임상 진행에 대한 사비르네투그의 효과
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
ADCS-iADL로 측정한 시간 절약 분석을 사용하여 평가한 위약과 비교하여 임상 진행에 대한 사비르네투그의 효과
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
ADAS-Cog13으로 측정한 시간 절약 분석을 사용하여 평가한 위약과 비교하여 sabirnetug가 임상 진행에 미치는 영향
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
CDR-SB로 측정한 시간 절약 분석을 사용하여 평가한 위약과 비교하여 임상 진행에 대한 사비르네투그의 효과
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
MMSE로 측정한 시간 절약 분석을 사용하여 평가한 위약과 비교하여 임상 진행에 대한 사비르네투그의 효과
기간: 80주차까지의 기준선
|
80주차까지의 기준선
|
|
|
Sabirnetug의 혈청 농도
기간: 투여 전 및 투여 후 최대 80주까지의 여러 시점
|
투여 전 및 투여 후 최대 80주까지의 여러 시점
|
|
|
뇌척수액(CSF) 내 sabirnetug 농도
기간: 76주차까지
|
76주차까지
|
|
|
CSF에서 sabirnetug-AβO(아밀로이드-β 올리고머) 복합체 측정을 통해 평가된 표적 참여
기간: 76주차까지
|
76주차까지
|
|
|
Change from Baseline in ADCS-iADL Score
기간: Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
기간: Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
기간: Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
기간: Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
기간: Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
기간: Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
기간: Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
기간: Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
기간: Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
기간: Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
기간: Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
기간: Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
기간: Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ACU193-201
- 2023-509807-34-00 (레지스트리 식별자: EU CT Number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .